Navigation Links
New Jersey Coalition Calls for Investigation of Private Wells to Protect Families from PFOA in Drinking Water

- Community groups react to news that DuPont's Teflon chemicals likely contaminate area residential wells. Eight of nine DuPont monitoring wells exceeded New Jersey's 'alert level.'

- Private residential well contamination with PFOA reported by NJDEP.

- Testing demanded of all private drinking water wells and warnings issued to residents in towns adjacent to DuPont because of high levels of PFOA.

DEEPWATER, N.J., June 9 /PRNewswire-USNewswire/ -- A coalition of environmental and labor groups are calling for the testing of private drinking water wells in four towns near DuPont's Chambers Works facility in Deepwater, N.J. They are concerned about the possible presence of the dangerous Teflon chemical, perfluorooctanoic acid (PFOA) and other perfluorinated compounds (PFCs).

(Logo: )

The coalition's call for testing of private wells by DuPont follows the company's disclosure to the New Jersey Department of Environmental Protection (NJDEP) that its groundwater monitoring wells showed contamination levels which exceeded the State of New Jersey's "alert level."

"Those whose drinking water comes from private wells have the right to know if they are drinking PFOA contaminated water," said Jane Nogaki, Vice Chair of NJ Environmental Federation. "Of particular concern are wells serving families with pregnant women and small children," she said noting a study of PFOA contamination of newborns released by Johns Hopkins Medical School in 2007.

"DuPont's sampling results, along with the NJDEP's information of private well contamination raises the possibility that up to 750 private residential drinking water wells in Salem County may suffer from PFOA contamination," said Shawn Gilchrist of the United Steelworkers Union.

Groundwater is the only source of drinking water for the nearby residents of Pennsville, Penns Grove, Carneys Point, and Oldmans Township and the results of DuPont's testing raises the possibility that common aquifers have been contaminated with PFOA and other PFCs.

DuPont's testing of nine on-site and off-site monitoring wells surrounding its Chambers Works plant showed PFOA results ranging from .012 parts per billion to 2.2 parts per billion. The nine monitoring wells were required by the NJDEP and were located at the plant's boundaries.

A year ago February, the NJDEP set the nation's safest drinking water guidance level for PFOA. New Jersey identified the safe "alert level" of only .04 parts per billion after finding PFOA contamination in drinking water supplies across the state. While all wells showed some PFOA content, eight of the nine monitoring wells exceeded New Jersey's "alert level."

The sampling results also suggest that DuPont's "interceptor wells," which are supposed to have contained the company's pollution, may not stop the spread of these contaminants into the surrounding communities.

At the present time, there are nearly two thousand Salem County residents who depend on private wells for their drinking water. Without further testing, we fear that many of these wells may draw water from a now contaminated aquifer.

"Clearly now that DuPont and the state know about the contamination, quick action to gather the private well data and address the danger is in everyone's interest," said Tracy Carluccio, Deputy Director of Delaware Riverkeeper Network.

"We demand these wells should be investigated for contamination with state oversight. To do less would be unconscionable," added Carluccio.

For more information:

Tracy Carluccio: 215-369-1188 or 215-692-2329 (cell)

Deputy Director, Delaware Riverkeeper Network

Jane Nogaki: 856-912-6790 (cell)

Vice Chair, NJ Environmental Federation

Shawn Gilchrist: 412-562-6968

United Steelworkers International Union

Denise Patel: (856) 465-1211 (cell)

Campaign Organizer, New Jersey Work Environment Council

Related scientific studies:

-- The Centers for Disease Control and John Hopkins University have

reported health impacts in newborn babies such as low birth weight and

reduced head circumference. (Source: Possible Etiologies of PFAA-Induced

Developmental Effects: Reflections from a Pediatric Perspective; Johns

Hopkins University, Baltimore, MD; U.S. Centers for Disease Control and

Prevention) Hidden List

-- PFOA has been found in the breast milk of nursing mothers, and has been

found in children between the ages of 2 and 12 at blood levels similar

to those found in adults. (Source: Study conducted by Kathleen Arcaro of

the University of Massachusetts Amherst--results are scheduled for

publication in Environmental Science and Technology ( Hidden List

Hidden List Hidden List Hidden List Hidden

List ); other breast milk studies reported in February and May 2007

Issue of Environmental Health Perspectives) Hidden List

SOURCE United Steelworkers (USW)
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Princeton HealthCare System Foundation Launches $115 Million Capital Campaign for New Hospital in New Jersey
2. New Jersey Dermatologist Volunteers Show Golf Enthusiasts How to Play Safe in the Sun
3. LMS CALM Shoulder Screen(TM) selected by New Jersey physician group to minimize obstetrical risks
4. 11 Pharmaceutical Titans Headline Chemistry Outsourcing Conference Program in September in New Jersey
5. New Jersey Dermatologists Gear Up for Fifth Season of Play Safe in the Sun at LPGAs Sybase Classic to Urge Outdoor Enthusiasts to Protect Skin
6. Rutgers research partner Stemcyte, Inc., expands to New Jersey
7. HealthSouth to Purchase The Rehabilitation Hospital of South Jersey
8. Experts Agree There is No Scientific Evidence of Health Risks in New Jersey Synthetic Turf Fields
9. New Jersey Leaders Join Forces to Battle Chronic Disease
10. LCA-Vision Announces the Opening of its 76th LasikPlus(R) Vision Center in Woodbridge, New Jersey
11. Teen Driving Experts at The Childrens Hospital of Philadelphia Support New Recommendations From the New Jersey Teen Driver Study Commission
Post Your Comments:
(Date:6/25/2016)... Long Beach, CA (PRWEB) , ... June 25, 2016 , ... ... from UCLA with Magna Cum Laude and his M.D from the David Geffen School ... San Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of ... recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at Work ... Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... awareness about the dangers associated with chronic pain and the benefits of holistic treatments, ... for individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) ...
(Date:6/24/2016)... ... 24, 2016 , ... The Pulmonary Hypertension Association (PHA) learned ... receive two significant new grants to support its work to advance research and ... by recognizing patients, medical professionals and scientists for their work in fighting pulmonary ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
Breaking Medicine Technology: